<DOC>
	<DOC>NCT01555008</DOC>
	<brief_summary>This Phase 1 study is intended to assess the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of LX4211 following once daily oral administration in subjects with type 2 diabetes mellitus (T2DM) and moderate to severe renal impairment.</brief_summary>
	<brief_title>Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Adults ≥18 to ≤80 years of age History of T2DM for at least 6 months prior to screening Moderate to severe renal impairment and not actively on dialysis Willing and able to perform selfmonitoring of blood glucose Willing and able to provide written informed consent History of type 1 diabetes mellitus, diabetic ketoacidosis (within the previous 6 months), or diabetes resulting from pancreatic disorder or secondary diabetes (from acromegaly and/or Cushing's disease) Subjects who have received a renal allograft Subjects expecting to require dialysis or to undergo kidney transplantation within 3 months of study dosing Presence of active hepatic disease or clinically significant abnormal liver function tests at Screening or planned study Day 1 Subjects with a history of heart attack, severe/unstable angina, or coronary revascularization procedure within 6 months prior to study Day 2 History of clinically significant cardiac arrhythmias within 1 year prior to study Day 2 Subjects with congestive heart failure Subjects with uncontrolled Stage III hypertension History of 2 or more emergency room visits, doctors' visits, or hospitalizations due to hypoglycemia within the 6 months prior to planned study Day 2 History of alcohol or illicit drug abuse within 1 year prior to Screening History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C Major surgery within 6 months prior to planned study Day 2 History of any malignancy within the last 5 years Triglycerides &gt;1000 mg/dL at Screening or planned study Day 1 History of any serious adverse reaction or hypersensitivity to an SGLT inhibitor Use of corticosteroids within 2 weeks prior to study Day 1 Use of any investigational drug within 30 days prior to study Day 1, or investigational protein or antibodies within 60 days of Day 1 Positive urine pregnancy test at Screening Positive urine screen for illicit drug abuse at Screening Prior exposure to LX4211</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>